Login to Your Account



Analysts Bullish on Benlysta as HGSI Reports First Revenue

By Trista Morrison


Monday, July 25, 2011
Human Genome Sciences Inc. reported net sales of $7.8 million for lupus drug Benlysta (belimumab) in the second quarter, the drug's first full quarter on the market since gaining FDA approval in March. (See BioWorld Today, March 11, 2011.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription